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Abstract 
Background: Perinatal exposure to endocrine-disrupting chemicals may affect thyroid 
hormones homeostasis and impair brain development. Chlordecone, an organochlorine 
insecticide widely used in the French West Indies has known estrogenic and progestin 
properties, but no data is available, human or animal, on its action on thyroid hormone system. 
Objectives: Our aim was to evaluate the impact of perinatal exposure to chlordecone on the 
thyroid hormone system of a sample of infants from the Timoun mother-child cohort in 
Guadeloupe and their further neurodevelopment.   
Methods: Chlordecone was measured in cord blood and breast milk samples. Thyroid 
stimulating hormone (TSH), free tri-iodothyronine (FT3), free thyroxine (FT4) were 
determined in child blood at 3 months (n = 111). Toddlers were further assessed at 18 months 
using an adapted version of the Ages and Stages Questionnaire (ASQ).  
Results: Cord chlordecone was associated with an increase in TSH in boys, whereas postnatal 
exposure was associated with a decrease in FT3 overall, and in FT4 among girls. Higher TSH 
level at 3 months was positively associated with the ASQ score of fine motor development at 
18 months among boys, but TSH did not modify the association between prenatal chlordecone 
exposure and poorer ASQ fine motor score.  
Conclusions: Perinatal exposure to chlordecone may affect TSH and thyroid hormone levels 
at 3 months, differently according to the sex of the infant. This disruption however did not 
appear to intervene in the pathway between prenatal chlordecone exposure and fine motor child 
development.  
Keywords: chlordecone, prenatal, breast feeding, thyroid hormone, children 
Funding sources: This work was supported by grants from the National Institute of Health and 
Medical Research (INSERM), the National Research Agency (ANR), the French Agency for 
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Environmental and Occupational Health Safety (AFSSET), the French Ministry of 
Environment, and the General Health Directorate (DGS). The authors declare they have no 
actual or potential competing financial interests. 
The research procedures were approved by the Guadeloupean Ethics Committee for biomedical 
studies involving human subjects (Project N° 03-04 01/10/2004).  
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1. Introduction 
Adequate maternal thyroid function in early pregnancy and adequate fetal thyroid function are 
essential for optimal fetal development, and subtle changes in circulating levels of thyroid 
hormone may have permanent effect on child development (Zoeller et al. 2002). 
Thyroid disruption resulting from exposure to environmental synthetic chemicals has been 
documented in wildlife and experimental animals (Brucker-Davis 1998). The picture is not as 
clear in humans but there is concern that exposure of pregnant women and infants to endocrine-
disrupting chemicals such as polychlorinated biphenyls (PCBs), dichlorodiphenyl 
trichloroethane (DDT) and its metabolite dichlorodiphenyl dichloroethylene (DDE), 
hexachlorobenzene and its metabolite pentachlorophenol, polybrominated diphenyl ethers 
(PBDEs), and nonylphenol may affect thyroid hormones homeostasis and impair growth and 
brain development (Boas et al. 2012).  
Several epidemiological studies have evaluated in particular the impact of prenatal PCBs 
exposure on child thyroid function, mainly at birth, relying on measures of exposure to PCBs 
during pregnancy and measures of thyroid hormone levels in cord blood or shortly after birth 
(prick tests). Some have found decreasing levels of free tri-iodothyronine (FT3) and free 
thyroxine (FT4) (Maervoet et al. 2007) or total T4 (Herbstman et al. 2008) or increase in thyroid 
stimulating hormone (TSH) (Alvarez-Pedrerol et al. 2008a; Chevrier et al. 2007) in relation 
with prenatal PCB exposure but most have found no association (Dallaire et al. 2008,  2009; 
Longnecker et al. 2000; Lopez-Espinosa et al. 2010; Ribas-Fito et al. 2003; Steuerwald et al. 
2000; Takser et al. 2005; Wang et al. 2005; Wilhelm et al. 2008). These contradictory findings 
may be partly due to the high variability of thyroid hormone levels at birth due to determinants 
such as gestational age, mode of delivery or neonatal health that are often not taken into account 
(Boas et al. 2012). When thyroid function has been evaluated among older children including 
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toddlers, results regarding consequences of perinatal exposure to PCBs are more consistent. 
Increase in TSH level or decrease in T3 (free or total) or total T4  have been observed in most 
studies (Alvarez-Pedrerol et al. 2008b; Darnerud et al. 2010; Herbstman et al. 2008; Koopman 
et al. 1994; Osius et al. 1999), except in Matsuura et al. (2001) and Dallaire et al. (2009).  
Chlordecone is an organochlorine insecticide that has intensively been used in the French West 
Indies from 1973 until 1993 to control banana root borers. Its persistence in the environment 
has resulted in a widespread contamination of soils, water sources and foodstuff (Dubuisson et 
al. 2007) leading to contamination of populations.  Chlordecone is neurotoxic, spermatotoxic, 
potentially carcinogenic in humans and possesses well defined estrogenic activity (Cannon et 
al., 1978; Hammond et al., 1979; Multigner et al., 2010). To our knowledge no data is available, 
human or animal, on its thyroid effects and/or its action on thyroid hormone system. 
A longitudinal mother-child study (the TIMOUN cohort) has been set up in Guadeloupe 
(French West Indies) to investigate the impact of perinatal environmental exposure to 
chlordecone on child development. In previous reports we have shown impairments of fine 
motor function at 18 months of age, specifically among boys (Boucher et al. 2013). Here we 
propose to study the association between chlordecone and thyroid hormone levels at 3 months, 
and the potential mediation of thyroid dysfunction, if any, on impairment of later child 
neurodevelopment. 
 
2. Methods 
2.1 Population and Data Collection 
The TIMOUN mother-child cohort included women in the second trimester of pregnancy that 
planned to give birth in the University Hospital of Pointe-à-Pitre and the General Hospital of 
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Basse-Terre (accounting for 70% of all deliveries in Guadeloupe) from December 2004 to 
December 2007. A detailed informed consent was obtained from 1068 pregnant women. The 
research procedures were approved by the Guadeloupean Ethics Committee for biomedical 
studies involving human subjects. A prenatal maternal face-to-face interview was conducted at 
enrolment by trained midwives to assess obstetrical, medical, personal, and socioeconomic 
characteristics. Maternal diseases, adverse delivery incidents as well as newborn 
anthropometric parameters and health information were collected at the end of pregnancy from 
medical records. Cord blood samples were obtained.  
A subgroup of infants was examined at 3 months of age. Exclusion criteria included maternal 
conditions such as history of diabetes, gestational diabetes mellitus, hypertension, epilepsy, 
human immunodeficiency virus infection, and long-term corticotherapy (n = 263). Exclusion 
criteria for newborns (n = 230) were not singleton, preterm, small for gestational age, APGAR 
< 7 at 5 min, severe respiratory distress, severe icterus, severe hypoglycemia and materno-foetal 
infection. For the remaining 575 participants, 365 could not be contacted because of incorrect 
address or refusal to participate, and 62 had incomplete data. This left 148 children for this 
analysis. Maternal interviews were conducted at that time (3 months after birth) to assess 
potential confounders and breast feeding status.  
 
2.2 Exposure assessment 
2.2.1 Prenatal exposure to chlordecone and other organochlorine compounds  
Cord blood sample were collected, processed and frozen at -30° until shipment on dry ice to 
Liege University (CART) for analysis. Chlordecone, PCB153 chosen as the representative of 
the whole mixture of PCBs, and p,p’-DDE were measured by gas chromatography–electron 
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capture detection.  Preparation of samples and the quantification method were as previously 
described (Multigner et al. 2010). The limit of detection (LOD) was 0.06 μg/L for chlordecone, 
and 0.05 μg/L for PCB-153 and p,p’-DDE.  
Total cholesterol and triglyceride concentrations in cord plasma samples were determined by 
standard enzymatic procedures (DiaSys Diagnostoc Systems GmbH; Holzheim, Germany) and 
total lipid concentrations were calculated as described by Bernert et al. 2007. 
Among the 148 cord blood samples, the median of cord chlordecone concentrations was 0.14 
µg/L. Due to more than 40% value <LOD and the possibility of nonlinear relation between 
chlordecone and thyroid hormones, we categorized cord chlordecone concentrations into 3 
classes : the first corresponding to concentrations <LOD and the two others cut at the median 
among detected concentrations. 
 
2.2.2 Postnatal Exposure to Chlordecone 
A 5-ml sample of breast milk was obtained by manual pressure on the breast at the 3 months 
postnatal visit from 68 out of 75 nursing mothers. Milk samples were frozen at -30°C and 
transferred on dry ice to Liege University for organochlorine analysis as previously described 
(Debier et al. 2003). The LOD for chlordecone in breast milk was 0.34 μg/L. Milk lipid 
concentrations were quantified by gravimetry (Debier et al. 2003).  
 
A variable describing postnatal chlordecone exposure through breastfeeding was created in 4 
categories combining duration of breast feeding (<3 months; ≥3 months) and tertiles of 
chlordecone concentration in breast milk as following: 0. no or less than 3 months breast 
feeding; 1. breast feeding at 3 months and chlordecone concentration < 0.50 ng/ml; 2. breast 
feeding at 3 months and chlordecone concentration > 0.50 ng/ml and <0.90 ng/ml; 3. breast 
8 
 
feeding at 3 months and chlordecone concentration ≥0.90 ng/ml. A value equal to the median 
concentration of chlordecone measured in breast milk was imputed to the infants breast fed at 
3 months for whom samples were not available (n=7). The category 1 that includes infants 
breast fed up to 3 months with a low chlordecone concentration in breast milk was chosen as 
the reference category. 
 
2.3 Thyroid Hormone Analysis 
A 3 mL blood sample was obtained from infants after local anaesthesia, processed and frozen 
at -30°C until shipment on dry ice to Rennes University Hospital for analysis. Due to limited 
serum volume, a priority order was introduced in the hormone determinations and not all 
hormones were measured in each sample. One child whose mother declared using medication 
for thyroid disease during pregnancy was excluded. This left 111 infants out of 148 for whom 
thyroid hormones were measured.   
 
TSH, FT3 and FT4 levels were determined by chimiluminescent assays on the automated 
ADVIA-Centaur XP (Siemens Healthcare Diagnostics, Tarrytown NY, USA). Results were 
expressed as concentrations (unit of milli-international units per liter for TSH, unit of picogram 
per milliliter for FT3 and FT4). The intra- and inter-assay coefficients of variation were < 2.5 
and <3.1, <5.3 and <4.1, and <4.7 and <5.8 % for TSH, FT3 and FT4, respectively. 
Hemolysis was present in several samples and the degree of hemolysis was ranked by visual 
inspection according to two levels (no or light hemolysis; moderate or strong hemolysis). 
Levels of TSH, FT3 and FT4 appeared to be influenced by the presence of hemolysis and by 
storage duration as previously reported (Panesar and Lit 2010). These characteristics of the 
samples were systematically taken into account in data analysis. 
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2.4 Assessment of infant neurodevelopment 
Among the 111 infants for whom thyroid hormone status was assessed at 3 months, 75 were 
part of a later assessment conducted at 18 months (Boucher et al. 2013) using an adapted version 
of the Ages and Stages Questionnaire, a screening test aimed at identifying children at risk for 
developmental delay (Bricker and Squires 1999). Each item from the communication, problem-
solving, fine motor and gross motor areas of both the 18- and the 20-month questionnaires was 
administered directly to the child by a trained research personnel. A total score was calculated 
for each area by adding the points obtained by the child. All scores were then converted to 
Intelligence Quotient (IQ)-like scores, with a mean of 100 and a SD of 15.  
 
2.5 Statistical analysis 
Multiple linear regression models were used to evaluate the relation between exposure to 
chlordecone, TSH and thyroid hormone levels. To satisfy criteria of normality, TSH, FT3 and 
FT4 serum levels and concentrations of p,p’-DDE and PCB-153 in cord blood were log-
transformed (Ln). Thereby, results are expressed in percent change in hormone levels 
approximated by (ebeta coefficient – 1)*100. 
Maternal factors such as maternal age at delivery (years), years of education (< 12 years; ≥ 12 
years), body mass index (BMI) before pregnancy (<25 kg/m2 , ≥25 kg/m2), fish consumption 
during pregnancy (grams per day), and the child’s birth weight z-score calculated from French 
reference curves (http://www.audipog.net/courbes_morpho.php) were considered a priori as 
susceptible to interfere in this association. Due to the limited sample size, we then tried to select 
the most parsimonious model using a manual backward selection to finally retain only variables 
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significant at 20% level. We systematically forced adjustments for sex, hemolysis level and 
storage duration. 
For each association with TSH, FT3, or FT4, three models were run including prenatal and 
postnatal exposure to chlordecone simultaneously since their correlation was moderate 
(r=0.20): the first model adjusted for hemolysis, storage duration and sex; the second model 
additionally included maternal and child covariates selected according to the method described 
above; the third one additionally included the concentrations of p,p’-DDE and PCB-153 and 
total lipids in cord blood. In this third model, cord concentrations of p,p’- DDE or PCB-153 
were treated as continuous variables since the shape of the association between cord 
concentrations of p,p’- DDE or PCB-153 in cord blood and 3-months thyroid hormone levels 
did not show any significant departure from linearity using generalized additive models (GAM). 
Values below LOD for p,p’-DDE and PCB-153 were imputed using a distribution-based simple 
imputation method (proc Lifereg SAS, Jin et al. 2011).  
For each hormone, results are presented for the overall sample and for each sex separately due 
to the known estrogenic activity of chlordecone. The shape of the associations between pre- or 
postnatal exposure to chlordecone and thyroid hormone levels (both in log scale) was further 
studied using GAM. The modeling relative to postnatal exposure was restricted to infants with 
a measure of breast milk chlordecone concentration (infants breast fed less than 3 months were 
excluded). 
The association between chlordecone prenatal exposure, thyroid hormone levels at 3 months 
and ASQ scores at 18 months was studied using multiple linear regression models including 
sex, maternal level of education and child age at examination, co-variables retained in the 
original analysis (Boucher et al. 2013), now restricted to the sample (n=75) for which we had 
simultaneously thyroid hormone levels at 3 months and ASQ scores at 18 months. The same 
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association was then estimated with or without inclusion of the thyroid hormone levels in the 
models (adding hemolysis and storage duration as co-variables), to evaluate their potential role 
as intermediate factors, and for each sex separately as in the original analysis.  
All analyses were performed using SAS 9.3. 
3. Results 
 
Sociodemographic and medical characteristics of mothers and infants are presented in Table 1. 
Most of the mothers were born in French West Indies, nearly half of them had more than 12 
years of education, four out of ten were not living with their partner and about one quarter was 
overweight at the beginning of pregnancy. Only 9% reported smoking, and 3.6% drinking 
alcohol during pregnancy. Two thirds of the infants were still breast fed at 3 months. 
Chlordecone was detected in 59% of cord blood and 71% of breast milk samples. In cord blood, 
the median concentration of chlordecone (0.13 μg/L) was lower than the median concentration 
of p,p’- DDE (0.30 μg/L) but slightly higher than the one of PCB-153 (0.10 μg/L). 
Concentrations of cord chlordecone concentration were moderately correlated with cord PCB-
153 (r= 0.24, p<0.05) and cord p,p’-DDE (r= 0.28, p<0.05) and chlordecone in breast milk 
(r=0.20, p<0.10).  No correlation was observed between cord PCB-153 and p,p’-DDE 
concentrations, or between both of these concentrations and chlordecone in breast milk 
(Supplementary Table A.1).  
TSH, FT3 and FT4 levels (Supplementary Table A.2) are within normal range expected at 3 
months (Kapelari et al. 2008). 
Increase in TSH levels was observed in association with prenatal exposure to chlordecone, the 
percent change being higher in the medium range exposure, and limited to boys (+89% 
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p<0.006) (Table 2). Adjustment for maternal confounders had minimal impact on estimates 
(Supplementary Tables A.3). PCB-153 and p,p’- DDE concentrations were not significantly 
associated with TSH levels and their inclusion in the model induced minimal changes in 
estimates. GAM models suggest a linear relation between prenatal exposure to chlordecone and 
TSH (both on a log scale) whereas among girls TSH appears to increase with postnatal exposure 
and then levels off (Supplementary Figure A.1). 
A decrease in the level of FT3 was observed in association with postnatal exposure to 
chlordecone, especially in the medium range (-6.6% p<0.03) (Table 3), only slightly attenuated 
(p<0.06) when PCB-153 and p,p’- DDE concentrations were taken into account. Splines show 
a steady decrease of FT3 with increasing postnatal exposure among boys only (Supplementary  
Figure A.2). 
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Finally a decrease in FT4 level associated with postnatal exposure to chlordecone was observed, 
but only among girls (-11% p<0.03) (Table 4). Splines confirm the monotonic decrease of FT4 
with increasing postnatal exposure among girls (Supplementary Figure A.3). In addition, 
prenatal exposure to p,p’-DDE was negatively associated with FT4 level among boys (p<0.03) 
but this did not modify the associations with prenatal chlordecone exposure.  
 
The association previously reported between higher prenatal chlordecone exposure and poorer 
ASQ fine motor score among boys in the same cohort remains of the same magnitude in the 
reduced sample (Table 5). When thyroid hormone levels are added to the model, a positive 
association between TSH level and ASQ fine motor score is observed in both sexes, but the 
inclusion of this variable does not modify the strength of the association between prenatal 
chlordecone exposure and ASQ fine motor score previously observed among boys. No 
association was observed between FT3 or FT4 levels and ASQ fine motor score (data not 
shown) 
 
4. Discussion 
We observed associations between perinatal exposure to chlordecone, TSH and thyroid 
hormone levels at 3 months, different according to the sex of the infant. Prenatal exposure to 
chlordecone was associated with an increase in the level of TSH in boys at 3 months, whereas 
postnatal exposure was associated with a decrease in FT3 mainly among boys, and in FT4 
among girls. In addition, we observed that prenatal exposure to p,p’- DDE was negatively 
associated with FT4 level among boys.  
Our results suggest for the first time a potential impact of perinatal exposure to chlordecone on 
thyroid function in infants, with specificities according to sex. Although no experimental data 
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are available to corroborate these findings, the impact of persistent organohalogens present in 
the environment on the thyroid hormone system is well recognized (Boas et al. 2012; Brouwer 
1998). The differential associations according to the sex of the infant may be expected since 
chlordecone has well defined estrogenic properties (Hammond et al. 1979) and closely 
resembled circulating estrogen in its male-targeted effects on pituitary peptides (Hong et al. 
1985). Indeed, both animals (Laessig et al. 2007; Mactutus and Tilson 1985) and human studies 
(Boucher et al. 2013) suggested sex-dependent behavioral and neurotoxic effects after prenatal 
or neonatal exposure to chlordecone  
Although a positive association was observed between TSH levels and ASQ score of fine motor 
development, TSH level did not appear to modify the association between higher prenatal 
chlordecone exposure and poorer ASQ fine motor score. This suggests that chlordecone 
developmental neurotoxicity may be mediated by the estrogen signaling pathway rather than 
by the thyroid endocrine system or by an interaction between these two hormonal systems 
(Duarte-Guterman et al. 2014).  
The main strength of this study is the longitudinal follow-up of perinatal exposure to 
chlordecone, thyroid hormones levels at 3 months and neurodevelopmental scores at 18 months, 
using biological measures of several other persistent contaminants. Children included in the 
survey were born at term, normal weight, with no birth defects, from a disease-free pregnancy. 
They were therefore not representative of the total newborn population and this excluded the 
possibility of appreciating the potential interaction of these conditions with chlordecone 
exposure on child thyroid dysfunction.  
TSH and thyroid hormone levels were determined using standard methods available in clinical 
practice.  Hemolysis and duration of storage had to be taken into account since they influenced 
circulating levels of FT3 and FT4 in particular, possibly as a result of destruction of thyroid-
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binding-globulin (Lingway and Holt 2012). TSH and thyroid hormone levels were measured 
away from birth at a moment more suitable for assessing infant’s thyroid function than shortly 
after delivery (Boas et al. 2012). It may not however have been the optimal age or the most 
relevant hormone biomarkers (circulating hormone levels) to assess the putative link with later 
neurodevelopment, since increased TSH level at 3 months unexpectedly appears to be 
associated with better fine motor score at 18 months. A complete overview of a potential 
pathway of action of chlordecone on neurodevelopment through disruption of thyroid function 
would also require simultaneous assessment of maternal thyroid hormone levels during 
pregnancy, despite inherent difficulties in their measurement due to high variability across 
pregnancy. 
Concentrations of chlordecone, pp’-DDE and PCB-153 in cord blood provided an estimate of 
fetal exposure to these contaminants. Since breast milk samples were taken at 3 months, an 
estimate of cumulative intake of chlordecone through breast feeding was possible only for 
infants still breast fed at that time (68%), the remaining 32% included both babies never breast 
fed and babies breastfed for a short time. To take into account the likely benefit of breast feeding 
in this analysis, the reference category was defined as infants breast fed at least 3 months with 
less contaminated milk. 
Finally the small sample size limits the scope of these findings. This lack of power may explain 
why we did not observe the previously reported association between prenatal PCB-153 
exposure and decrease in T3 or T4 levels in childhood, despite PCB-153 concentrations of the 
same order of magnitude than those reported in European birth cohorts (Govarts et al. 2012). 
We did however observe a decrease in FT4 level among 3-months old boys in association with 
p,p’-DDE concentration in cord blood. Such an association was previously reported among 
newborns with similar levels of prenatal exposure to p,p’-DDE by Maervoet et al. (2007) and 
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Brucker-Davis et al. (2011), or in relation with much higher exposure in Thailand where 
decreased TT4 was observed (Asawasinsopon et al. 2006). This association has not however 
been reported by others (Alvarez-Pedrerol et al. 2008b; Darnerud et al. 2010; Schell et al. 2004; 
Steuerwald et al. 2000; Takser et al. 2005).  
5. Conclusions 
In conclusion, perinatal exposure to chlordecone may affect TSH and thyroid hormone levels 
at 3 months, differently according to the sex of the infant. Experimental work is needed to 
support these findings. 
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Table 1. Sociodemographic and medical characteristics of mothers and infants (n=111) 
Characteristics % or  
mean ± SD 
Maternal  
Age (years) 30.7 ± 6.8 
Birthplace (% French West Indies) 80.2 
Education (% ≥ 12 years)       48.6 
Marital status a  
  Alone 25.9 
  With a partner 54.6 
  Alone with family members 19.4 
Parity 1.1 ± 1.2 
Maternal BMI (kg/m²) (% ≥ 25) 26.1 
Maternal weight gain during pregnancy (g/week) a 367 ± 229 
Smoking during pregnancy (% yes) 9.0 
Alcohol drinking during pregnancy a (% yes) 3.6 
Fish consumption during pregnancy (g/day) a 130 ± 153 
Infant  
Age at (weeks) 13.5 ± 1.2 
Sex (% male) 52.2 
Gestational age (weeks) 39.1 ± 1.1 
Birth weight (g)      3258 ± 383 
Birth weight z-score 0.1 ± 0.9 
Breast-fed at 3 months (% yes) 67.6 
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SD: Standard Deviation; BMI: Body Mass Index 
a Missing values for marital status (n=3), maternal weight gain during pregnancy (n=2), 
alcohol drinking during pregnancy (n=1), fish consumption during pregnancy (n=5). 
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Table 2: Percent change in TSH (mlU/L) with prenatal exposure to chlordecone and 
exposure through breast feeding by sex  
Analyte (µg/L) N Percent change 
(95% CI) a 
p-value N Percent change 
(95% CI) b 
p-value 
Overall       
Chlordecone in cord (class)       
<0.06 46 0  44 0  
0.06-0.31 36 50.7 (17.2, 93.9) 0.002 35 46.8 (10.8, 94.3) 0.008 
>0.31 29 24.1 (-4.8, 61.8) 0.11 27 24.7 (-6.9, 67.2) 0.14 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 35 3.8 (-21.9, 37.9) 0.80 35 7.6 (-20.5, 45.5) 0.63 
<0.5 25 0  23 0  
0.5 – 0.9 26 30.0 (-4.4, 76.6) 0.09 26 30.0 (-6.8, 80.9) 0.12 
≥ 0.9 24 17.5 (-13.4, 59.2) 0.30 22 20.1 (-13.5, 66.7) 0.27 
ln PCB-153 - - - 106 0.01 (-1.00, 1.01) c 0.99 
ln p,p’-DDE - - - 106 -0.2 (-0.82, 0.04) c 0.55 
Boys       
Chlordecone in cord (class)       
<0.06 18 0  18 0  
0.06-0.31 23 93.7 (30.7, 186.9) 0.001 22 89.3 (21.3, 195.6) 0.006 
>0.31 17 49.9 (0.4, 123.9) 0.05 16 61.3 (2.0, 155.0) 0.04 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 19 -3.1 (-35.4, 45.5) 0.88 19 -1.6 (-36.6, 52.8) 0.94 
<0.5 14 0  13 0  
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0.5 – 0.9 14 24.6 (-20.8, 96.0) 0.33 14 20.9 (-26.6, 99.2) 0.45 
≥ 0.9 11 7.6 (-33.2, 73.5) 0.76 10 11.6 (-35.0, 91.6) 0.68 
ln PCB-153 - - - 56 -0.32 (-1.93, 1.27) c 0.68 
ln p,p’-DDE - - - 56 0.04 (-0.93, 1.01) c 0.94 
Girls       
Chlordecone in cord (class)       
<0.06 28 0  26 0  
0.06-0.31 13 18.1 (-17.4, 68.7) 0.35 13 14.2 (-24.3, 72.5) 0.52 
>0.31 12 2.7 (-28.3, 47.1) 0.88 11 -1.5 (-35.7, 51.1) 0.95 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 17 20.8 (-19.7, 81.7) 0.36 16 31.0 (-16.6, 105.4) 0.23 
<0.5 11 0  10 0  
0.5 – 0.9 12 37.7 (-10.1, 111.1) 0.14 12 41.8 (-11.5, 127.3) 0.14 
≥ 0.9 13 45.5 (-3.1, 118.6) 0.07 12 47.4 (-5.2, 128.9) 0.08 
ln PCB-153 - - - 50 -0.27 (-1.83, 1.26) c 0.71 
ln p,p’-DDE - - - 50 -0.03 (-1.04, 0.99) c 0.95 
TSH: Thyroid stimulating hormone; PCB: Polychlorinated biphenyl; DDE: dichlorodiphenyl 
dichloroethylene 
a: adjusted for hemolysis (no or weak, moderate or high), storage duration (continuous), (sex), 
level of education (less than 12 years, at least 12 years) 
b: additionally adjusted for ln PCB-153 (continuous), ln p,p’-DDE (continuous), total lipids 
(continuous) 
c: express in percent change in hormone levels for a 10% increase in exposure 
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Table 3: Percent change in FT3 (pg/mL) with prenatal exposure to chlordecone and exposure through breast feeding by sex 
Analyte (µg/L) N Percent change 
(95% CI) a 
p-value N Percent change (95% CI) b p-value 
Overall       
Chlordecone in cord (class)       
<0.06 46 0  44 0  
0.06-0.31 36 3.3 (-1.7, 8.4) 0.20 35 3.9 (-1.6, 9.5) 0.17 
>0.31 29 -0.7 (-5.7, 4.5) 0.77 27 0.5 (-4.9, 6.3) 0.85 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 36 -2.4 (-7.5, 3.0) 0.37 35 -1.9 (-7.3, 3.7) 0.50 
<0.5 25 0  23 0  
0.5 – 0.9 26 -6.6 (-11.9, -0.8) 0.03 26 -6.0 (-11.8, 0.1) 0.06 
≥ 0.9 24 -3.8 (-9.3, 2.0) 0.20 22 -2.9 (-8.7, 3.3) 0.36 
ln PCB-153 - - - 106 -0.05 (-0.23, 0.14) c 0.62 
ln p,p’-DDE - - - 106 -0.05 (-0.16, 0.08) c 0.47 
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Boys       
Chlordecone in cord (class)       
<0.06 18 0  18 0  
0.06-0.31 23 6.3 (-1.6, 14.8) 0.12 22 5.9 (-3.0, 15.4) 0.19 
>0.31 17 0.6 (-7.1, 9.0) 0.87 16 1.2 (-7.2, 10.6) 0.80 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 19 -3.8 (-11.1, 4.1) 0.32 19 -2.8 (-10.7, 5.8) 0.50 
<0.5 14 0  13 0  
0.5 – 0.9 14 -7.3 (-15.3, 1.5) 0.10 14 -7.8 (-16.4, 1.6) 0.10 
≥ 0.9 11 -5.5 (-14.0, 3.7) 0.22 10 -4.5 (-13.8, 5.9) 0.37 
ln PCB-153 - - - 56 -0.03 (-0.33, 0.28) c 0.84 
ln p,p’-DDE - - - 56 -0.11 (-0.31, 0.08) c 0.22 
Girls       
Chlordecone in cord (class)       
<0.06 28 0  26 0  
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0.06-0.31 13 0.7 (-5.4, 7.3) 0.81 13 1.8 (-5.1, 9.1) 0.61 
>0.31 12 -2.2 (-8.2, 4.2) 0.48 11 -0.7 (-7.7, 6.8) 0.84 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 17 -2.4 (-9.0, 4.8) 0.50 16 -2.4 (-9.5, 5.3) 0.53 
<0.5 11 0  10 0  
0.5 – 0.9 12 -6.3 (-13.1, 1.0) 0.09 12 -5.0 (-12.5, 3.0) 0.21 
≥ 0.9 13 -2.3 (-9.1, 4.9) 0.51 12 -1.4 (-8.6, 6.4) 0.71 
ln PCB-153 - - - 50 -0.06 (-0.32, 0.20) c 0.64 
ln p,p’-DDE - - - 50 -0.01 (-0.18, 0.16) c 0.95 
FT3: Free tri-iodothyronine; PCB: Polychlorinated biphenyl; DDE: dichlorodiphenyl dichloroethylene 
a adjusted for hemolysis (no or weak, moderate or high), storage duration (continuous), (sex) 
b additionally adjusted ln PCB-153 (continuous), ln p,p’-DDE (continuous), total lipids (continuous) 
c express in percent change in hormone levels for a 10% increase in exposure 
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Table 4: Percent change in FT4 (pg/mL) with prenatal exposure to chlordecone and exposure through breast feeding by sex  
Analyte (µg/L) N Percent change 
(95% CI) a 
p-value N Percent change (95% 
CI) b 
p-value 
Overall       
Chlordecone in cord (class)       
<0.06 46 0  44 0  
0.06-0.31 36 -2.6 (-8.6, 4.0) 0.43 35 0.6 (-6.3, 8.0) 0.87 
>0.31 29 2.3 (-4.3, 9.5) 0.49 27 4.1 (-3.2, 12.0) 0.28 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 35 -1.4 (-8.1, 5.9) 0.70 35 -0.5 (-7.7, 7.1) 0.89 
<0.5 25 0  23 0  
0.5 – 0.9 26 -4.9 (-12.1, 2.9) 0.21 26 -4.6 (-12.2, 3.7) 0.26 
≥ 0.9 24 -2.7 (-10.1, 5.3) 0.49 22 -3.1 (-10.9, 5.1) 0.44 
ln PCB-153 - - - 106 -0.14 (-0.39, 0.10) c 0.25 
ln p,p’-DDE - - - 106 -0.18 (-0.34, -0.01) c 0.04 
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Boys       
Chlordecone in cord (class)       
<0.06 18 0  18 0  
0.06-0.31 23 0.5 (-9.2, 11.3) 0.92 22 4.2 (-7.0, 16.6) 0.47 
>0.31 17 2.3 (-8.0, 13.8) 0.66 16 4.6 (-6.9, 17.6) 0.43 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 19 1.8 (-8.4, 13.1) 0.74 19 3.1 (-7.9, 15.3) 0.57 
<0.5 14 0  13 0  
0.5 – 0.9 14 -1.0 (-12.4, 11.7) 0.86 14 -2.5 (-14.0, 10.6) 0.70 
≥ 0.9 11 1.8 (-10.7, 16.0) 0.79 10 4.6 (-9.2, 20.4) 0.53 
ln PCB-153 - - - 56 -0.10 (-0.49, 0.30) c 0.63 
ln p,p’-DDE - - - 56 -0.31 (-0.57, -0.03) c 0.03 
Girls       
Chlordecone in cord (class)       
<0.06 28 0  26 0  
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0.06-0.31 13 -1.5 (-9.7, 7.5) 0.73 13 -0.6 (-10.1, 10.0) 0.91 
>0.31 12 2.0 (-6.6, 11.5) 0.65 11 1.1 (-9.1, 12.4) 0.84 
Chlordecone in milk (class)       
Unexposed (breastfeeding<3 months) 17 -7.5 (-16.1, 1.9) 0.11 16 -6.9 (-16.6, 4.0) 0.20 
<0.5 11 0  10 0  
0.5 – 0.9 12 -11.0 (-19.9, -1.2) 0.03 12 -10.0 (-19.9, 1.2) 0.08 
≥ 0.9 13 -9.3 (-18.1, 0.3) 0.06 12 -9.8 (-19.2, 0.7) 0.07 
ln PCB-153 - - - 50 0.04 (-0.37, 0.45) c 0.84 
ln p,p’-DDE - - - 50 -0.04 (-0.30, 0.21) c 0.74 
FT4: Free thyroxine; PCB: Polychlorinated biphenyl; DDE: dichlorodiphenyl dichloroethylene 
a adjusted for hemolysis (no or weak, moderate or high), storage duration (continuous), (sex), maternal age (continuous), fish consumption 
(continuous) 
b additionally adjusted for ln PCB-153 (continuous), ln p,p’-DDE (continuous), total lipids (continuous) 
c express in percent change in hormone levels for a 10% increase in exposure 
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Table 5: Linear regression coefficients of ASQ fine motor score at 18 months and prenatal exposure to chlordecone (µg/L) with or 
without TSH level at 3 months 
Analyte N β (95% CI) a  p-value N β (95% CI) b p-value N β (95% CI) c p-value 
Overall          
Chlordecone in cord (class)          
<0.06 µg/L 65 0  31 0  31 0  
0.06-0.24 µg/L 39 1.8 (-4.3 ; 7.9) 0.56 19 0.03 (-9.2 ; 9.2) 0.99 19 -2.0 (-11.7 ; 7.6) 0.68 
>0.24 µg/L 44 -7.7 (-13.6 ; -1.8) 0.01 25 -7.3 (-16.0 ; 1.3) 0.09 25 -7.6 (-17.3 ; 2.1) 0.12 
log TSH (mlU/L)  - - - - - - - 8.3 (0.6 ; 16.0) 0.03 
Boys          
Chlordecone in cord (class)          
<0.06 µg/L 25 0  9 0  9 0  
0.06-0.24 µg/L 18 0.8 (-9.4 ; 11.0) 0.88 11 -3.5 (-21.9 ; 14.8) 0.70 11 -7.4 (-25.8 ; 11.0) 0.41 
>0.24 µg/L 23 -10.1 (-19.4 ; -0.8) 0.03 15 -14.0 (-30.6 ; 2.6) 0.09 15 -13.8 (-31.2 ; 3.7) 0.12 
log TSH (mlU/L)  - - - - - - - 10.9 (-1.3 ; 23.2) 0.08 
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Girls          
Chlordecone in cord (class)          
<0.06 µg/L 40 0  22 0  22 0  
0.06-0.24 µg/L 21 1.6 (-6.4 ; 9.6) 0.69 8 0.4 (-10.7 ; 11.4) 0.95 8 -1.7 (-13.7 ; 10.2) 0.77 
>0.24 µg/L 21 -5.5 (-13.3 ; 2.4) 0.17 10 -1.1 (-11.3 ; 9.0) 0.82 10 -2.3 (-14.1 ; 9.6) 0.70 
log TSH (mlU/L)  - - - - - - - 8.0 (-2.5 ; 18.5) 0.13 
a Adjusted for maternal educational level (less than 12 years, at least 12 years), child age (continuous), (sex). Estimated from n=148 
children with measures of cord Chlordecone and ASQ fine motor. 
b Same model as (a) but estimated from the subgroup of n=75 children with measure of TSH 
c Same subgroup as (b) adjusted for maternal educational level (less than 12 years, at least 12 years), child age (continuous), (sex), 
hemolysis (no or weak, moderate or high), storage duration (continuous) 
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